Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series
PLOS One · 2025
DOI: 10.1371/journal.pone.0337237 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Mengzhi Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Crown Ethers, Lung Neoplasms, Quinazolines. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Joint Funds of the Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Primary results of the CORIN trial indicated that, compared with chemotherapy, icotinib significantly improved 3-year disease-free survival (DFS) in patients with Epidermal Growth Factor Receptor (EGFR)-mutated stage IB non-small cell lung cancer (NSCLC). However, evidence regarding the outcomes of adjuvant icotinib in patients with high-risk factors remains limited. This retrospective study evaluated the efficacy and safety of adjuvant icotinib in patients with EGFR-mutated high-risk stage IB NSCLC. We enrolled 37 patients with completely resected EGFR-mutated high-risk stage IB NSCLC. The median follow-up time was 31 months, and the 3-year DFS rate was 91.4%. Two patients experienced disease recurrence and were successfully switched to osimertinib upon identification of an EGFR (T790M) mutation. Although overall survival (OS) and central nervous system (CNS)-DFS data were not mature, no deaths or central nervous system metastases were observed by the end of follow-up. 29 (78.4%) patients experienced grade 1–2 adverse events (AEs), no grade 3 or higher AEs occurred. This study suggests a potential DFS benefit and well-tolerated profile of adjuvant icotinib in patients with EGFR-mutated high-risk stage IB NSCLC. However, longer-term follow-up is necessary to assess the long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
- Department of Thoracic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
- Department of Central Laboratory, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
- Department of Central Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
ORCID-Profile: Mengzhi Cheng, Jianbin Zhang
Förderung
- the Joint Funds of the Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Cheng, M., Zhang, J., Jin, L., Yu, C., Xie, Z., Li, D., Gu, Q., & Shen, Q. (2025). Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series. PLOS One. https://doi.org/10.1371/journal.pone.0337237
Vancouver
Cheng M, Zhang J, Jin L, Yu C, Xie Z, Li D, et al. Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series. PLOS One. 2025. doi:10.1371/journal.pone.0337237
BibTeX
@article{Cheng2025,
author = {Cheng, Mengzhi and Zhang, Jianbin and Jin, Lili and Yu, Caihua and Xie, Zhonghai and Li, Dong and Gu, Qinhua and Shen, Qibin},
title = {Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0337237}
}
EUVIMED